Cryo-Cell International (FRA:ZCY) Notes Receivable: €0.00 Mil (As of Feb. 2026)


FRA:ZCY Cryo-Cell International Inc FRA:ZCY
63 GF Score
Price €2.86
GF Value €4.50
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Cryo-Cell International Notes Receivable?

Cryo-Cell International FRA:ZCY +2.88% 63 Notes Receivable is €0.00 Mil as of Feb. 2026. GuruFocus rates FRA:ZCY with a GF Score™ of 63/100 and a GF Value™ of €4.50 (Possible Value Trap). The stock has 4 warning signs investors should review.

Cryo-Cell International's Notes Receivable for the quarter that ended in Feb. 2026 was €0.00 Mil.

Cryo-Cell International Notes Receivable Related Terms

Cryo-Cell International Notes Receivable Historical Data

* Premium members only.

The historical data trend for Cryo-Cell International's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cryo-Cell International Notes Receivable Chart

Cryo-Cell International Annual Data
Trend Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23 Nov24 Nov25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Cryo-Cell International Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:ZCY
63GF Score
Cryo-Cell International Inc FRA:ZCY
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cryo-Cell International Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of €0.00 Mil mean?
Cryo-Cell International (FRA:ZCY) has a Notes Receivable of €0.00 Mil as of Feb. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Cryo-Cell International and its competitors.
Is Cryo-Cell International's Notes Receivable too high?
Cryo-Cell International's current Notes Receivable is €0.00 Mil. Overall, Cryo-Cell International has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cryo-Cell International's Notes Receivable compare to CCM and CDIX?
Cryo-Cell International's Notes Receivable of €0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Healthcare Providers & Services company?
A good Notes Receivable depends on the Healthcare Providers & Services industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Cryo-Cell International and its competitors. Cryo-Cell International's current Notes Receivable is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryo-Cell International stock overvalued right now?
Based on GuruFocus' analysis, Cryo-Cell International (FRA:ZCY) is currently considered Possible Value Trap. The stock's GF Value™ is €4.50, compared to a current price of €2.86 — trading 36.4% below its estimated fair value. The current Notes Receivable is €0.00 Mil. Cryo-Cell International's overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Cryo-Cell International (FRA:ZCY), the current Notes Receivable is €0.00 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cryo-Cell International (FRA:ZCY) Overvalued in 2026?

Based on GuruFocus' analysis, Cryo-Cell International stock appears to be undervalued. The current stock price of €2.86 is trading 36.4% below its estimated GF Value™ of €4.50. GuruFocus considers Cryo-Cell International to be Possible Value Trap.

Key valuation signals for FRA:ZCY:

  • Notes Receivable: €0.00 Mil
  • GF Value™: €4.50 vs. price of €2.86 (36.4% below fair value)
  • GF Score™: 63/100 with 4 warning signs

No single metric tells the full story. See the FRA:ZCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cryo-Cell International Business Description

Other Exchanges CCEL:USA
Address 700 Brooker Creek Boulevard, Suite 1800, Oldsmar, FL, USA, 34677
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
63GF Score

Get the complete analysis for FRA:ZCY

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.86
Price
€4.50
GF Value